Physician profile
Michael H Lee
NPI 1174739957
$432.70
in general payments reported to CMS, 2019-2025
9 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $101 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $160.69 | 2023 | Patient-Fitted Tmj Reconstructive Prosthesis System |
| Celgene Corporation | $78.03 | 2024 | Zeposia |
| Lilly USA, LLC | $58.36 | 2025 | Omvoh |
| Janssen Biotech, INC. | $43.69 | 2025 | Tremfya |
| Enterra Medical, INC. | $37.57 | 2025 | |
| Abbvie INC. | $23.14 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.95 | 2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $13.27 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,464.18 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.